{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:06:14Z","timestamp":1788527174981,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10067-019-04449-w","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T03:50:28Z","timestamp":1550721028000},"page":"1413-1424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"N\u00fc\u00dflein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heitzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Le Bars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"4449_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SLJ, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1\u201325","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4449_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"4449_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","volume":"55","author":"PD Kiely","year":"2016","unstructured":"Kiely PD (2016) Biologic efficacy optimization\u2014a step towards personalized medicine. Rheumatology (Oxford) 55:780\u2013788","journal-title":"Rheumatology (Oxford)"},{"key":"4449_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"4449_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Teng J, Becker JC, Westhovens R (2008) Results of a two-year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953\u2013963","journal-title":"Arthritis Rheum"},{"key":"4449_CR6","first-page":"553","volume":"32","author":"R Westhovens","year":"2014","unstructured":"Westhovens R, Kremer J, Emery P, Russell A, Alten R, Barre E, Dougados M (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553\u2013562","journal-title":"Clin Exp Rheumatol"},{"key":"4449_CR7","first-page":"S28","volume":"31","author":"K Yoshida","year":"2013","unstructured":"Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH (2013) Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol 31:S28\u2013S32","journal-title":"Clin Exp Rheumatol"},{"key":"4449_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","volume":"40","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A (2010) A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 40:2\u201314","journal-title":"Semin Arthritis Rheum"},{"key":"4449_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.22860","volume":"68","author":"P Vashisht","year":"2016","unstructured":"Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K (2016) Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res (Hoboken ) 68:1478\u20131488","journal-title":"Arthritis Care Res (Hoboken )"},{"key":"4449_CR10","unstructured":"Orencia 250 mg powder for concentrate for solution for infusion. (2017). \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/19714\/SPC\n                    \n                  \/. Accessed May 21, 2018"},{"key":"4449_CR11","unstructured":"Product monograph: Orencia (abatacept). (2015). \n                    http:\/\/www.bmscanada.ca\/static\/products\/en\/pm_pdf\/ORENCIA_EN_PM.pdf\n                    \n                  . Accessed October 10, 2018"},{"key":"4449_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/1744666X.2016.1133295","volume":"12","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Sulli A, Paolino S, Pizzorni C (2016) CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol 12:417\u2013425","journal-title":"Expert Rev Clin Immunol"},{"key":"4449_CR13","doi-asserted-by":"crossref","unstructured":"N\u00fc\u00dflein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M (2014) Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 15(14)","DOI":"10.1186\/1471-2474-15-14"},{"key":"4449_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol 31:315\u2013324","journal-title":"Arthritis Rheumatol"},{"key":"4449_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","volume":"277","author":"World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects","year":"1997","unstructured":"World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects (1997) JAMA 277:925\u2013926","journal-title":"JAMA"},{"key":"4449_CR16","unstructured":"ICH Harmonised Tripartite Guideline Guideline for good clinical practice (2001). J Postgrad Med 47:199\u2013203"},{"key":"4449_CR17","unstructured":"Olsen J (2007) Good Epidemiological Practice (GEP): IEA Guidelines for Proper Conduct in Epidemiological Research"},{"key":"4449_CR18","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/rmdopen-2017-000538","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, Chartier M, Elbez Y, Rauch C, Le Bars M (2017) Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open 3:e000538. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2017-000538","journal-title":"RMD Open"},{"key":"4449_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin N Am 35:745\u2013757","journal-title":"Rheum Dis Clin N Am"},{"key":"4449_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"issue":"Suppl2","key":"4449_CR21","doi-asserted-by":"publisher","first-page":"FRI0298","DOI":"10.1136\/annrheumdis-2014-eular.3004","volume":"73","author":"A Finckh","year":"2014","unstructured":"Finckh A, Gomez-Reino J, Iannone F, Lie E, Canhao H, Pavelka K, Turesson C, Mariette X, Gottenberg JE, Hetland M, ABA oboP-E-Ro (2014) The impact of DMARD co-therapy on abatacept effectiveness in rheumatoid arthritis patients. A pan-European analysis of RA registries. Ann Rheum Dis 73(Suppl2):FRI0298. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.3004","journal-title":"Ann Rheum Dis"},{"key":"4449_CR22","doi-asserted-by":"publisher","first-page":"e000040","DOI":"10.1136\/rmdopen-2014-000040","volume":"1","author":"A Finckh","year":"2015","unstructured":"Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canh\u00e3o H, Mariette X, Turesson C (2015) The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 1:e000040","journal-title":"RMD Open"},{"key":"4449_CR23","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F Keyser De","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41:1761\u20131765","journal-title":"J Rheumatol"},{"key":"4449_CR24","first-page":"S201","volume":"64","author":"H Forsblad-d'Elia","year":"2012","unstructured":"Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH (2012) Drug survival, efficacy and predictors for survival on tocilizumab in real-life patients with rheumatoid arthritis; results from the Swedish Biologics Register. Arthritis Rheumatol 64:S201","journal-title":"Arthritis Rheumatol"},{"key":"4449_CR25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","volume":"71","author":"JD Greenberg","year":"2012","unstructured":"Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71:1134\u20131142","journal-title":"Ann Rheum Dis"},{"key":"4449_CR26","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10067-015-3066-z","volume":"34","author":"Z Rotar","year":"2015","unstructured":"Rotar Z, Hocevar A, Rebolj KA, Praprotnik S, Tomsic M (2015) Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry. Clin Rheumatol 34:1787\u20131793","journal-title":"Clin Rheumatol"},{"key":"4449_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3899\/jrheum.091066","volume":"37","author":"LJ Maxwell","year":"2010","unstructured":"Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 37:234\u2013245","journal-title":"J Rheumatol"},{"key":"4449_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/ijr.10.52","volume":"5","author":"M Schiff","year":"2010","unstructured":"Schiff M, Poncet C, Le BM (2010) Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int J Clin Rheumatol 5:581\u2013591","journal-title":"Int J Clin Rheumatol"},{"key":"4449_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3899\/jrheum.120906","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC (2013) Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 40:787\u2013797","journal-title":"J Rheumatol"},{"key":"4449_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/annrheumdis-2016-eular.6326","volume":"75","author":"R Alten","year":"2016","unstructured":"Alten R, N\u00fc\u00dflein H, Galeazzi M, Lorenz HM, Mariette X, Cantagrel A, Chartier M, Elbez Y, Rauch C, Le Bars M (2016) Do predictors of IV abatacept retention depend on the line of rheumatoid arthritis treatmen: 12-month interim analysis of the observational, prospective ACTION study. Ann Rheum Dis 75:202","journal-title":"Ann Rheum Dis"},{"key":"4449_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","volume":"16","author":"HG N\u00fc\u00dflein","year":"2015","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M (2015) Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 16:176. \n                    https:\/\/doi.org\/10.1186\/s12891-015-0636-9","journal-title":"BMC Musculoskelet Disord"},{"key":"4449_CR32","first-page":"489","volume":"34","author":"HG N\u00fc\u00dflein","year":"2016","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le BM (2016) Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 34:489\u2013499","journal-title":"Clin Exp Rheumatol"},{"key":"4449_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","volume":"54","author":"CRM Gabay","year":"2015","unstructured":"Gabay CRM, Scherer A, Finckh A (2015) Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54:1664\u20131672. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kev019","journal-title":"Rheumatology (Oxford)"},{"key":"4449_CR34","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis. Arthritis Rheumatol 68:1346\u20131352","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"4449_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2015-eular.6633","volume":"74","author":"TWJ Huizinga","year":"2015","unstructured":"Huizinga TWJ, Connolly SE, Johnsen A, Zhu J, Furst DE, Bykerk VP, Burmester GR, Combe BG, Wong DA, Trouw LA, Toes REM, Emery P (2015) Effect of anti-cyclic citrullinated peptide 2 immunoglobulin M serostatus on efficacy outcomes following treatment with abatacept plus methotrexate in the AVERT trial. Ann Rheum Dis 74(Suppl 2):234\u2013235","journal-title":"Ann Rheum Dis"},{"key":"4449_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709\u2013714","journal-title":"Ann Rheum Dis"},{"key":"4449_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3899\/jrheum.170007","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM (2018) Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis: a US National Observational Study. J Rheumatol 45:32\u201339. \n                    https:\/\/doi.org\/10.3899\/jrheum.170007","journal-title":"J Rheumatol"},{"key":"4449_CR38","doi-asserted-by":"publisher","unstructured":"Bozec A, Luo Y, Ngdahl C et al. (2018) Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner. Arthritis Res Ther 20. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket224","DOI":"10.1093\/rheumatology\/ket224"},{"key":"4449_CR39","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","volume":"52","author":"VK Ranganath","year":"2013","unstructured":"Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, Sarkisian C, Kremer JM, Furst DE, Paulus HE (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:1809\u20131817","journal-title":"Rheumatology (Oxford)"},{"key":"4449_CR40","doi-asserted-by":"publisher","unstructured":"McWilliams DF, Walsh DA (2016) Factors predicting pain and early discontinuation of tumour necrosis factor-a-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskeletal Disorders. \n                    https:\/\/doi.org\/10.1186\/s12891-12016-11192-12897\n                    \n                   doi:27515300","DOI":"10.1186\/s12891-12016-11192-12897"},{"key":"4449_CR41","doi-asserted-by":"publisher","unstructured":"Kang EH, Yinzhu J, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC (2018) Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 7:e007393. \n                    https:\/\/doi.org\/10.1161\/JAHA.117.007393","DOI":"10.1161\/JAHA.117.007393"},{"key":"4449_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00296-014-2999-x","volume":"34","author":"J Lee","year":"2014","unstructured":"Lee J, Mason R, Martin L, Barnabe C (2014) Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study. Rheumatol Int 34:1449\u20131453","journal-title":"Rheumatol Int"},{"key":"4449_CR43","unstructured":"Alten R, N\u00fc\u00dflein H, Galeazzi M, Lorenz H-M, Mariette X, Cantagrel A, Chartier M, Desachy G, Poncet C, Rauch C, Le Bars M (2015) Body mass index does not influence the efficacy of abatacept in patients with RA who are biologic naive: 6-month results from a real-world, international prospective study. Arthritis Rheumatol 67(suppl 10):abstract 553. \n                    https:\/\/acrabstracts.org\/abstract\/body-mass-index-does-not-influence-the-efficacy-of-abatacept-in-patientswith-ra-who-are-biologic-naive-6-month-results-from-a-real-world-international-prospective-study\/"},{"key":"4449_CR44","doi-asserted-by":"publisher","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Nusslein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M (2017) Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive: 6-month results from a real-world, international, prospective study. RMD Open 3:e000345. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2016-000345","journal-title":"RMD Open"},{"key":"4449_CR45","first-page":"1","volume":"8","author":"M Harigai","year":"2016","unstructured":"Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, Koike T (2016) Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 8:1\u20138","journal-title":"Mod Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s10067-019-04545-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04449-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04449-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04449-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T19:14:52Z","timestamp":1582226092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04449-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4449"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04449-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-019-04545-x","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article listed above was initially published with incorrect copyright information. Upon publication of this Correction, the copyright of this article changed to \u201cThe Author(s)\u201d. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RA: grant\/research support: Bristol-Myers Squibb; speakers bureau: Bristol-Myers Squibb. XM: grant\/research support: Biogen, Pfizer, UCB; speakers bureau: Bristol-Myers Squibb, LFB, GSK, Pfizer, UCB. H-ML: consulting fees: AbbVie, Bristol-Myers Squibb, Roche-Chugai, UCB, MSD, GSK, Sobi, Medac, Novartis, Janssen-Cilag, AstraZeneca, Pfizer, Actelion. HN: consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB. MG: none declared. FN: grant\/research support: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, Roche; speakers bureau: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb; consultant: Pfizer, MSD, Roche, UCB, AbbVie, Bristol-Myers Squibb, Janssen, Lilly. MC: employee: Bristol-Myers Squibb. JH: consultant: Bristol-Myers Squibb. CP: consultant: Bristol-Myers Squibb. CR: shareholder and employee: Bristol-Myers Squibb. MLB: shareholder and employee: Bristol-Myers Squibb (at time of study).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice Guidelines, and the Good Epidemiological Practice Guidelines. All enrolled patients provided informed consent in accordance with local laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}